article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer. The FDA approved the first MEK inhibitor, a melanoma drug from Novartis, in 2013.

Immunity 130
article thumbnail

Steroid Use During ICI Treatment Lessens Effectiveness in Patients With NSCLC

Pharmacy Times

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy. months) and 6.4 months).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

Touchstone Books; 2013. Time Enough for Love. Putnam’s Sons; 1973. Hyperbole and a Half: Unfortunate Situations, Flawed Coping Mechanisms, Mayhem, and Other Things That Happened. Rao KV, Gulbis AM, Mahmoudjafari Z. 2022;5(11):1112-1120. doi:10.1002/jac5.1693 4. 6 challenges facing community oncology practices.

article thumbnail

STAT+: Pharmalittle: We’re reading about chemo drugs failing quality tests, Gavi losing U.S. funding, and more

STAT

… Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries at risk of ineffective treatments and potentially fatal side effects, an investigation by  The Bureau of Investigative Journalism  (TBIJ) reveals. And of course, do keep in touch.

article thumbnail

STAT+: Study points to new ‘king on the block’ for treatment of chronic lymphocytic leukemia

STAT

When it hit the market in 2013, the drug revolutionized the treatment of these cancers and represented a major step forward from chemotherapy and some other drugs at the time. NEW ORLEANS – One of the best therapies for some types of lymphoma and leukemia has been a drug called ibrutinib, made by AbbVie.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? There is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.

article thumbnail

How Myo-inositol Can Improve Hashimoto’s Symptoms

The Thyroid Pharmacist

In one study done in 2013, patients with autoimmune thyroiditis were split into two groups, with one group being treated with 600 milligrams of myo-inositol and 83 mcg of selenium (selenomethionine) per day for six months, and the other being treated with just selenium. doi:10.1155/2013/424163. 2013 Feb;17(4):537-40.